Shreeram Aradhye M.D.
Net Worth
Last updated:
What is Shreeram Aradhye M.D. net worth?
The estimated net worth of Dr. Shreeram Aradhye M.D. is at least $1,927,515 as of 15 Dec 2021. He owns shares worth $189,915 as insider and has received compensation worth at least $1,737,600 in Dicerna Pharmaceuticals, Inc..
What is the salary of Shreeram Aradhye M.D.?
Dr. Shreeram Aradhye M.D. salary is $434,400 per year as Executive Vice President & Chief Medical Officer in Dicerna Pharmaceuticals, Inc..
How old is Shreeram Aradhye M.D.?
Dr. Shreeram Aradhye M.D. is 62 years old, born in 1963.
What stocks does Shreeram Aradhye M.D. currently own?
As insider, Dr. Shreeram Aradhye M.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Dicerna Pharmaceuticals, Inc. (DRNA) | Executive Vice President & Chief Medical Officer | 4,969 | $38.22 | $189,915 |
What does Dicerna Pharmaceuticals, Inc. do?
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.
Shreeram Aradhye M.D. insider trading
Dicerna Pharmaceuticals, Inc.
Dr. Shreeram Aradhye M.D. has made 2 insider trades in 2021, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 7,025 units of DRNA stock on 15 Sep 2021. As of 15 Dec 2021 he still owns at least 4,969 units of DRNA stock.
Dicerna Pharmaceuticals key executives
Dicerna Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Bob D. Brown (60) Executive Vice President of R&D and Chief Scientific Officer
- Dr. Douglas M. Fambrough III (56) Co-Founder, Chief Executive Officer, Pres & Director
- Dr. Shreeram Aradhye M.D. (62) Executive Vice President & Chief Medical Officer
- Mr. Douglas W. Pagan (53) Chief Financial Officer
- Mr. James B. Weissman (63) Executive Vice President & Chief Operating Officer